NOVT

Novanta Inc. Common Stock

$147.85

-10.33%
Jul 7, 2026
Bobby Quantitative Model
Novanta Inc. supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. The company operates through two segments: Automation Enabling Technologies and Medical Solutions, with Automation Enabling Technologies generating the majority of revenue. As a niche player in precision technologies, Novanta is currently attracting investor attention due to its strong YTD rally of over 45%, driven by robust demand in medical and industrial automation, though concerns about valuation and insider selling have emerged. Recent news highlights a major institutional investor betting $45 million on the stock, signaling confidence in its recovery potential despite a flat performance over the past year.

People also watch

SanDisk

SanDisk

SNDK

Analysis
Amphenol

Amphenol

APH

Analysis
Corning Inc.

Corning Inc.

GLW

Analysis
II-VI Incorporated

II-VI Incorporated

COHR

Analysis
Keysight Technologies

Keysight Technologies

KEYS

Analysis

NOVT 12-Month Price Forecast

Historical Price
Current Price $147.85
Average Target $147.85
High Target $170.02749999999997
Low Target $125.67249999999999

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Novanta Inc. Common Stock's 12-month outlook, with a consensus price target around $192.21 and implied upside of +30.0% versus the current price.

Average Target

$192.21

2 analysts

Implied Upside

+30.0%

vs. current price

Analyst Count

2

covering this stock

Price Range

$118 - $192

Analyst target range

Buy
0 (0%)
Hold
1 (50%)
Sell
1 (50%)

Only 2 analysts cover Novanta, indicating limited institutional interest. The consensus recommendation is not explicitly provided, but the average estimated EPS is $4.14, with a range of $4.11 to $4.16. The average revenue estimate is $1.125 billion. Without a target price, the implied upside/downside cannot be calculated. The low number of analysts suggests higher uncertainty and less efficient price discovery. The narrow EPS range ($4.11-$4.16) indicates some consensus on near-term earnings, but the lack of ratings and target prices limits the usefulness of this data. Investors should be cautious as limited coverage can lead to higher volatility and potential mispricing.

Drowning in data?

Find the real signal!

NOVT Technical Analysis

Novanta is in a strong uptrend over the past year, with a 1-year price change of +21.73%, significantly outperforming the S&P 500's +19.1%. The current price of $161.72 sits at 94% of its 52-week range (52-week low: $98.27, high: $171.85), indicating the stock is near its highs and reflecting strong momentum but also potential overextension. The stock's beta of 1.675 implies it is 67.5% more volatile than the market, amplifying both upside and downside moves. Short-term momentum shows a divergence: the 1-month change is -4.08%, while the 3-month change is +38.18%, suggesting a recent pullback within a powerful medium-term rally. The 1-month decline contrasts with the 1-year uptrend, which could signal a temporary consolidation or profit-taking after a sharp run-up. The relative strength over 3 months is +24.62% versus the S&P 500, confirming strong relative performance. Key support is at the 52-week low of $98.27, while resistance is at the 52-week high of $171.85. A breakout above $171.85 would signal a continuation of the uptrend, while a breakdown below recent support near $150 could indicate a deeper correction. Given the high beta, investors should expect amplified swings and manage position sizes accordingly.

Beta

1.68

1.68x market volatility

Max Drawdown

-27.0%

Largest decline past year

52-Week Range

$98-$172

Price range past year

Annual Return

+14.8%

Cumulative gain past year

PeriodNOVT ReturnS&P 500
1m-5.4%+1.4%
3m+20.8%+10.6%
6m+14.9%+8.4%
1y+14.8%+20.5%
ytd+33.0%+9.7%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

NOVT Fundamental Analysis

Novanta's revenue trajectory is growing, with estimated revenue of $1.125 billion for the current fiscal year, though specific quarterly figures are not available. The company's growth is driven by its Automation Enabling Technologies segment, which benefits from trends in robotics and precision manufacturing. The estimated revenue growth implies a forward PS ratio of 4.44x, suggesting the market is pricing in continued expansion. Profitability is solid: net margin is 5.49%, gross margin is 41.59%, and operating margin is 11.90%. Net income is positive (EPS of $0.0123), indicating the company is profitable. Margins appear stable, though detailed quarterly trends are unavailable. The company has a strong balance sheet with a debt-to-equity ratio of 0.26, indicating low leverage, and a current ratio of 3.69, reflecting ample liquidity. Return on equity (ROE) is 4.10%, and return on assets (ROA) is 4.56%, suggesting efficient use of capital. Free cash flow data is not provided, but the PCF ratio of 67.97x implies a high valuation relative to cash flow, which could be a concern if cash generation does not improve.

Quarterly Revenue

N/A

N/A

Revenue YoY Growth

N/A

YoY Comparison

Gross Margin

N/A

Latest Quarter

Free Cash Flow

N/A

Last 12 Months

Open an Account, get $2 TSLA now!

Valuation Analysis: Is NOVT Overvalued?

Since net income is positive, the primary valuation metric is the PE ratio. The trailing PE is 80.95x, while the forward PE is 39.03x, indicating that the market expects significant earnings growth. The gap between trailing and forward PE implies a 52% expected earnings increase, which is aggressive. Compared to the industry (Hardware, Equipment & Parts), Novanta trades at a premium; the industry average PE is typically lower, though specific industry data is not provided. The PS ratio of 4.44x and EV/Sales of 5.63x also suggest a premium valuation. Historically, the current PE is near the high end of its range, as the stock has rallied sharply. The PEG ratio is negative (-4.65x) due to negative earnings growth expectations, which is a red flag. Overall, the valuation appears stretched, with the market pricing in optimistic growth assumptions that may not materialize.

PE

80.9x

Latest Quarter

vs. Historical

N/A

5-Year PE Range 17x~59x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

28.2x

Enterprise Value Multiple